Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Pfizer backs its highest grosser Lipitor

Pfizer’s Lipitor, a blood cholesterol lowering drug, is a popular one the among general population. However now that a generic competition for the drug has arrived in the market the company has devised discounts and incentives for patients, insurers and companies that process prescriptions that will, at least for the next six months, make the brand name drug about as cheap as or cheaper than the generics.

30 Nov 2011

ACGME approves Cedars-Sinai's neurology residency training program

The Accreditation Council for Graduate Medical Education has approved a neurology residency training program at Cedars-Sinai Medical Center. Recruitment of the first group of three residents is under way through the 2012 "match," a process in which an independent organization pairs applicants with programs to meet the preferences of each.

30 Nov 2011

Mayo Clinic becomes FUS Foundation's new Research Award recipient

The Focused Ultrasound Surgery Foundation has announced that its Research Awards Program is funding a Mayo Clinic study that will be the first to use U.S. commercial database information to compare the costs of three minimally-invasive treatments for symptomatic uterine fibroids, a benign and often debilitating condition that affects more than one in four American women.

30 Nov 2011

Anemia, high blood pressure linked to risk of silent strokes in children with SCD

A team of researchers from the Johns Hopkins Children's Center, Vanderbilt University and elsewhere have demonstrated that high blood pressure and anemia together put children with sickle cell disease (SCD) at serious danger for symptomless or so-called "silent" strokes, although either condition alone also signaled high risk.

30 Nov 2011

Kessler Foundation scientists to investigate cognitive reserve in TBI

Denise Krch, PhD, and James Sumowski, PhD, research scientists in the Neuropsychology and Neuroscience Laboratory at Kessler Foundation, received a $379,000 grant for a three-year study of cognitive reserve in people with traumatic brain injury.

30 Nov 2011

Exposure to TCE, PERC and CCI4 may increase risk of Parkinson's

A University of Kentucky faculty member is a contributing author on a new study demonstrating a connection between a common solvent chemical and Parkinson's disease. Dr. Franca Cambi of the UK Kentucky Neuroscience Institute collaborated with researchers from across the U.S. on a paper recently published in the Annals of Neurology.

29 Nov 2011

FDA assigns priority-review designation for ELIQUIS NDA for stroke prevention in atrial fibrillation

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for ELIQUIS® (apixaban), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

29 Nov 2011

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Commission (EC) has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS).

29 Nov 2011

URMC earns Gold Seal of Approval for Palliative Care Program

In the latest development in its decades-long leadership in the area of palliative care, the University of Rochester Medical Center's Palliative Care Program is one of the first nationwide to earn advanced certification from the Joint Commission, the nation's predominant standards-setting and accrediting body in health care.

29 Nov 2011

Ferrer introduces citicoline oral solution medical food

Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.

29 Nov 2011

Individuals with mood disorders twice as likely to have heart attacks

Depression may have more far-reaching consequences than previously believed. Recent data suggests that individuals who suffer from a mood disorder could be twice as likely to have a heart attack compared to individuals who are not depressed.

29 Nov 2011

New way of monitoring blood pressure wins innovation and technology award

Revolutionary device developed by University of Leicester, in collaboration with biotech SME HealthStats in Singapore and the NHS, wins Times Higher Education Award.

29 Nov 2011

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that they have initiated a Phase 3 clinical trial evaluating the efficacy and safety of EYLEA (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

28 Nov 2011

Henry Schein launches new integrated comprehensive solution to treat sleep apnea

Henry Schein, Inc., the largest provider of health care products and services to office-based practitioners, today announced the launch of its Sleep Complete™ program, a new integrated comprehensive solution that provides all of the information and products necessary for the successful implementation of dental sleep medicine into the dental practice.

28 Nov 2011

Moleac launches NurAiD II in France and Belgium

Biopharmaceutical Company Moleac has announced the launch in France and Belgium of NurAiD II. NurAiD II is a natural health supplement engineered to stimulate neuroplasticity and recovery.

25 Nov 2011

Transplantation of new neurons into damaged area of the brain could restore brain functions

Without neurons reacting to the blood leptin level, the brain does not control the feeling of hunger and fullness. This type of genetic defects results in severe obesity in humans and animals.

25 Nov 2011

Peter and Melanie Munk Charitable Foundation donates $18M to UHN cardiac centre

Dr. Robert Bell, President and CEO of University Health Network (UHN), announced today that the Peter and Melanie Munk Charitable Foundation is donating $18 million to the Peter Munk Cardiac Centre at UHN. This new gift brings the total investment by Peter and Melanie Munk in UHN to $65 million.

24 Nov 2011

Researchers take a step toward neuronal replacement therapy

A new study has revealed that immature neurons taken from healthy mouse embryos can repair damaged brain circuitry and partially normalize metabolism when transplanted into adult mice that have grown morbidly obese due to a genetic deficiency.

24 Nov 2011

Carefully selected young, healthy neurons can repair brain circuitry

Neuron transplants have repaired brain circuitry and substantially normalized function in mice with a brain disorder, an advance indicating that key areas of the mammalian brain are more reparable than was widely believed.

24 Nov 2011

NIH grant to support Cedars-Sinai's Department of Neurology research

The National Institutes of Health has awarded a four-year, $1.4 million grant to Cedars-Sinai's Department of Neurology to study an unexpected recent discovery: After ischemic stroke - the type caused by a clogged artery but with no bleeding into the brain - a normal protein that plays a positive role in blood clotting escapes intact arteries and damages healthy brain cells.

24 Nov 2011